Advertisement

Drugs

, Volume 78, Issue 13, pp 1363–1370 | Cite as

Peramivir: A Review in Uncomplicated Influenza

  • Lesley J. Scott
Adis Drug Evaluation
  • 209 Downloads

Abstract

Intravenous peramivir (Alpivab™; Rapivab®; Rapiacta®; PeramiFlu®), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults and children from the age of 2 years. This article, written from an EU perspective, reviews the clinical use of peramivir in this indication and summarizes its pharmacological properties. In large, randomized, double-blind, multicentre trials in previously healthy adults with uncomplicated influenza, a single infusion of peramivir 600 mg significantly shortened the median time to resolution of influenza symptoms compared with placebo and was noninferior to the recommended oseltamivir regimen in terms of this primary outcome. Albeit data are limited, results from a noncomparative phase 3 trial in paediatric patients (≈ 95% of whom were aged ≥ 2 years) with acute uncomplicated influenza receiving the recommended dose of peramivir were generally consistent with those in adults. Peramivir was generally well tolerated in children and adults participating in these clinical trials, with most adverse events of mild to moderate intensity. Given its simple single-dose regimen and with intravenous administration offering a potential advantage over oral administration in individuals with nausea, vomiting or having difficulty in swallowing, peramivir provides an additional option for treating uncomplicated influenza infection in adults and children from the age of 2 years.

Notes

Acknowledgements

During the peer review process, the manufacturer of peramivir was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Ghebrehewet S, MacPherson P, Ho A. Influenza. BMJ. 2016.  https://doi.org/10.1136/bmj.i6258.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    European Centre for Disease Prevention and Control. Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza. 2017. http://www.ecdc.europa.eu. Accessed 2 Aug 2018.
  3. 3.
    Hurt AC. The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol. 2014;8:22–9.CrossRefPubMedGoogle Scholar
  4. 4.
    McLaughlin MM, Skoglund EW, Ison MG. Peramivir: an intravenous neuraminidase inhibitor. Expert Opin Pharmacother. 2015;16(12):1889–900.CrossRefPubMedGoogle Scholar
  5. 5.
    Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem. 2000;43(19):3482–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Chand P, Kotian PL, Dehghani A, et al. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antinifluenza activity. J Med Chem. 2001;44(25):4379–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006;69(1):39–45.CrossRefPubMedGoogle Scholar
  8. 8.
    Katzen J, Ison MG. Peramivir: evidence to support the use of the first approved intravenous therapy for influenza. Future Virol. 2015;10(8):937–48.CrossRefGoogle Scholar
  9. 9.
    Smee DF, Huffman JH, Morrison AC, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother. 2001;45:743–8.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Dapat C, Kondo H, Dapat IC, et al. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009–2010 and 2010–2011 influenza seasons in Japan. Antiviral Res. 2013;99(3):261–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Fage C, Tu V, Carbonneau J, et al. Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors. Antivir Ther. 2017;22(8):711–6.CrossRefPubMedGoogle Scholar
  12. 12.
    BioCryst. RAPIVAB® (peramivir injection): US prescribing information. 2018. https://www.fda.gov/. Accessed 2 Aug 2018.
  13. 13.
    Leang SK, Kwok S, Sullivan SG, et al. Peramivir and laninamivir susceptibility of circulating influenza A and B viruses. Influenza Other Respir Viruses. 2014;8(2):135–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Abed Y, Pizzorno A, Boivin G. Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation. Antimicrob Agents Chemother. 2012;56(8):4375–80.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Boltz DA, Ilyushina NA, Arnold CS, et al. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res. 2008;80(2):150–7.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology. 2008;374(1):198–209.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Pascua PNQ, Mostafa HH, Marathe BM, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection. Sci Rep. 2017;7(7345):1–15.Google Scholar
  18. 18.
    Kitano M, Itoh Y, Kodama M, et al. Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques. Antimicrob Agents Chemother. 2011;55(11):4961–70.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Okomo-Adhiambo M, Sleeman K, Lysen C, et al. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 southern hemisphere season. Influenza Other Respir Viruses. 2013;7(5):645–58.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Meijer A, Rebelo-de-Andrade H, Correia V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013. Antiviral Res. 2014;110:31–41.CrossRefPubMedGoogle Scholar
  21. 21.
    Takashita E, Meijer A, Lackenby A, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014. Antiviral Res. 2015;117:27–38.CrossRefPubMedGoogle Scholar
  22. 22.
    Hurt AC, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. Antiviral Res. 2016;132:178–85.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Gubareva LV, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016. Antiviral Res. 2017;146:12–20.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    World Health Organization. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility: Geneva, November 2011 and June 2012. Wkly Epidmiol Rec. 2012;87:369–74.Google Scholar
  25. 25.
    McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses. 2013;7(Suppl 1):25–36.CrossRefPubMedGoogle Scholar
  26. 26.
    Okomo-Adhiambo M, Sleeman K, Ballenger K, et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses. 2010;2(10):2269–89.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Takashita E, Ejima M, Itoh R, et al. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill. 2014;19(1):1–6.CrossRefGoogle Scholar
  28. 28.
    Takashita E, Fujisaki S, Shirakura M, et al. Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016. Euro Surveill. 2016;21(24):1–6.CrossRefGoogle Scholar
  29. 29.
    BioCryst. Alpivab (peramivir): summary of product characteristics. 2018. http://www.ema.europa.eu/. Accessed 2 Aug 2018.
  30. 30.
    Saisho Y, Ishibashi T, Fukuyama H, et al. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects. Antivir Ther. 2017;22(4):313–23.CrossRefPubMedGoogle Scholar
  31. 31.
    Zhang D, Du A, Zhang L, et al. Pharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjects. Xenobiotica. 2015;45(3):239–43.CrossRefPubMedGoogle Scholar
  32. 32.
    Funatsu Y, Tasaka S, Asami T, et al. Pharmacokinetics of intravenous peramivir in the airway epithelial lining fluid of healthy volunteers. Antivir Ther. 2016;21(7):621–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Matsuo Y, Ishibashi T, Hollister AS, et al. Population pharmacokinetics of peramivir in healthy volunteers and influenza patients. Antimicrob Agents Chemother. 2015;59(11):6755–62.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Kohno S, Kida H, Mizuguchi M, et al. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568–74.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 2011;55(11):5267–76.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Nakamura S, Miyazaki T, Izumikawa K, et al. Efficacy and safety of intravenous peramivir compared with oseltamivir in high-risk patients infected with influenza A and B viruses: a multicenter randomized controlled study. Open Forum Infect Dis. 2017;4(3 ofx129):1–8.Google Scholar
  37. 37.
    Vanchiere J, Plunkett S, Annamalai R, et al. Single dose IV peramivir is safe and effective in the treatment of pediatric influenza [abstract no. 2335 plus poster]. In: ID Week 2017. 2017.CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Public Health England. PHE guidance on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza. 2017. http://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/648758/PHE_guidance_antivirals_influenza_201718_FINAL.pdf. Accessed 2 Aug 2018.
  39. 39.
    European Medicines Agency. Oseltamavir: summary of product characteristics. 2012. http://www.ema.europa.eu. Accessed 2 Aug 2018.
  40. 40.
    GlaxoSmithKline UK. Relenza 5 mg/dose inhalation powder: summary of product characteristics. 2015. http://www.medicines.org.uk/. Accessed 2 Aug 2018.
  41. 41.
    Nguyen-van-Tam JS, Venkatesan S, Muthuri SG, et al. Neuraminidase inhibitors: who, when, where? Clin Microbiol Infect. 2015;21:222–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Li TC, Chan MC, Lee N. Clinical implications of antiviral resistance in influenza. Viruses. 2015;7(9):4929–44.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Moodley A, Bradley JS, Kimberlin DW. Antiviral treatment of childhood influenza: an update. Curr Opin Pediatr. 2018;30(3):438–47.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations